Compare Estee Lauder Companies Inc (EL) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Sana Biotechnology Inc — how do they compare? Estee Lauder Companies Inc trades at $82.84 (market cap $29.78B), while Sana Biotechnology Inc trades at $3.21 (market cap $987.94M). The key difference: Estee Lauder Companies Inc is far larger — about 30.1× Sana Biotechnology Inc's market cap, and Estee Lauder Companies Inc pays a 1.7% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| EL | SANA | |
|---|---|---|
Market Cap | $29.78B | $987.94M |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $5.92 |
52-Week Low | $67.23 | $2.68 |
Enterprise Value | $35.95B | $962.13M |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $82.72, up 2.3% with recent earnings beats but faces fundamental challenges including a negative net income margin of -1.67% and elevated P/E ratio of 147.8. Technical indicators show bearish momentum with support at $81 and resistance at $84. The company maintains strong gross margins at 74.71% and positive analyst sentiment with 44% buy ratings and $90.60 consensus target.
While recent earnings outperformance and strong brand positioning provide upside potential, investors face risks from declining revenue trends, negative profitability, and high valuation multiples. The stock's near-term direction will depend on Q2 2026 earnings delivery and management's ability to restore sustainable growth amid competitive pressures.
Sana Biotechnology (SANA) trades at $3.225, down 9.66% on the day, reflecting market volatility despite a bullish technical signal and strong analyst support. The company shows significant financial losses with a -$244.17M net income for 2025 and negative cash flows, but has beaten earnings expectations in two of the last three quarters. Recent news highlights clinical progress in cell therapies and a $69M capital raise via an ATM facility in May 2026.
The investment case balances high-risk fundamentals against promising clinical developments and overwhelming analyst optimism. While substantial losses and cash burn present clear risks, the company's scientific advancements and 82% buy rating from analysts suggest potential long-term upside for risk-tolerant investors in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
